Diabetes drug may ease dangerous fluid retention in liver disease

NCT ID NCT07684326

Recruiting now Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a drug originally for diabetes, can help people with liver cirrhosis who have ascites (fluid buildup in the belly). The goal is to see if it reduces the need for fluid drainage procedures, lowers hospital stays, and improves quality of life. The trial includes 52 adults with cirrhosis and ascites, comparing dapagliflozin against standard care over three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin
What this could lead to: If it works, this could offer a new way to manage ascites and reduce hospital visits for people with advanced liver disease.
What could go wrong: This is an early combined Phase 2/3 trial with only 52 participants, so results may not apply broadly. Dapagliflozin can cause side effects like dehydration or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCITES HEPATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCITES HEPATIC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Haram Hospital
RECRUITING

Giza, 12556, Egypt

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.